ABVC
ABVC BIOPHARMA, INC.
Next earnings Aug 11, 2026
Last earnings -4.1% on 2026-03-03
$1.53
▲ +5.52%$1.53▼ -16.85%
over 1Y
L $0.91EODHDH $4.74
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+5.5%
1W+15.9%
1M+10.1%
3M+53.0%
YTD-30.1%
1Y-16.8%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 6 analysts
Sell
Conservative balance sheet (liabilities/equity 0.70x); but unprofitable (net margin -2671.8%).
ABVC BIOPHARMA, INC. shows $296K in FY2025 revenue, a -2671.8% net margin, and -71.2% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $296K |
| Gross profit | $351K | $683K | -$150K | $509K | — |
| Operating income | -$11.7M | -$15.1M | -$6.77M | -$4.71M | -$7.15M |
| Net income | -$12.8M | -$16.4M | -$7.79M | -$4.90M | -$7.91M |
| Diluted EPS | -$0.51 | -$5.19 | -$1.80 | -$0.42 | -$0.39 |
| Net margin | — | — | — | — | -2671.8% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$39.0M
EV / EBITDA—
EV / Sales131.7
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-20.3%
FCF yield-7.7%
Quality & risk
ROIC (est.)-47.6%
Free cash flow-$3.01M
Total debt$756K
Net cash-$74.0K
Altman Z-Score-3.42 distress
Piotroski F-Score4/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+61.2%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — late filing notice (2026-05-15). Worth a closer look.
Recent filings
all on EDGAR ↗10-QPeriod ending 2026-03-312026-05-18open ↗NT 10-QPeriod ending 2026-03-312026-05-15open ↗POS AMFiling2026-03-27open ↗8-KPeriod ending 2026-03-272026-03-27open ↗DEF 14APeriod ending 2026-03-262026-03-05open ↗10-KPeriod ending 2025-12-312026-03-03open ↗10-Q/APeriod ending 2025-09-302026-03-03open ↗8-KPeriod ending 2026-03-032026-03-03open ↗PRE 14APeriod ending 2026-02-052026-02-05open ↗8-K/APeriod ending 2025-04-302026-01-16open ↗424B4Filing2025-11-14open ↗424B4Filing2025-11-14open ↗
Frequently asked
- Is ABVC BIOPHARMA, INC. (ABVC) a buy?
- ABVC currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.70x); but unprofitable (net margin -2671.8%).
- What is ABVC BIOPHARMA, INC.'s quality score?
- ABVC scores 29.823529411764703/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001173313, latest 10-Q filed 2026-05-18) · EODHD · as of 6/26/2026, 6:56:55 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.